• CBD-infused beverages market expected to make over $14,600 million by the end of 2026
• CBD beverages are becoming more popular as cannabis-infused goods become legalized across the United States and around the world
• Simply Sonoma has two CBD-infused beverages on the docket: an alcohol-free, CBD wine product and a low-carb, low-sugar CBD sparkling product

Cannabidiol, or CBD, is gaining the attention of enthusiastic cannabis consumers around the world. The list of products that contain CBD is growing, with one of the most popular new products being CBD-infused beverages. Simply Sonoma, a company committed to offering CBD products for the environmentally conscious consumer, is branching out into the beverage space with an alcohol-free, CBD wine product as well as low-carb, low-sugar Pinot Noir/CBD sparkling product. “The global CBD-infused beverages market was valued at around USD$3,400 million in 2020 and is expected to make over USD$14,600 million by the end of 2026, with a CAGR of approximately 27.5% between 2021 and 2026,” reported Facts and Factors (https://ibn.fm/D3gas). “The market for CBD-infused drinks is largely driven by the rising authorization and certification for recreational cannabis in countries, such as the United States and Canada. “Furthermore, because of the increasing incidence of numerous respiratory disorders, there is a growing movement away from smoking cannabis and adopting healthier edible options, which is pushing the market growth,” the article continued. “Furthermore, the common accessibility of CBD-infused drinks such as coffee, fruit punch, cannabis cola, tea, and other CBD-infused beverages across various legal marijuana outlets further augments the global industry.” Noting that CBD is the second most common active component in cannabis, the article observed that the substance is an important component of medicinal marijuana. “Despite the fact that CBD is a component of marijuana, it has no hallucinogenic effects on the human mind. ‘In people, CBD displays no effects suggestive of any misuse or dependency potential,’ according to a World Health Organization report. To date, there has been no evidence of public health issues linked to the use of pure CBD and its derivatives.” F&F reported that CBD beverages are becoming more popular as cannabis-infused goods become legalized across the United States and around the world. “CBD’s appeal has been fueled by its expanding availability combined with a growing health trend, with more and more people opting for ‘better-for-you’ alternatives to sugary drinks. CBD-infused drinks of various types provide a great alternative, with health advantages to boot, because CBD beverages are sourced from a natural source.” Simply Sonoma prides itself on using natural sources for the ingredients it uses. The company has contracted with Sonoma Biologics, a premium hemp cultivator, to grow its strains. The company also has access to some of the best grapes in the world, which Simply Sonoma is using to formulate its CBD-infused grape products. The company has two CBD-infused beverages on the docket: an antioxidant, alcohol-free, CBD wine product and a low-carb, low-sugar Pinot Noir/CBD sparkling product. Simply Sonoma is a different kind of natural company. The company is committed to creating high-quality products using all-natural, organically sun-grown, plant-based ingredients. In addition, because the company is committed to minimizing its carbon footprint, it operates off the grid, relying on solar power. For more information, or to invest in Simply Sonoma, visit the company’s website at www.SimplySonoma.org. NOTE TO INVESTORS: The latest news and updates relating to Simply Sonoma are available in the company’s newsroom at https://ibn.fm/Sonoma

• Red White & Bloom Brands is building a multi-state operation in the cannabis and hemp industries through state subsidiaries focused on markets in Florida, Michigan, Illinois, Arizona and California
• The company is now rapidly building up its cultivation and retail operations in Florida, advancing from regulatory approval in the state last month to the startup of growing activity to supply existing and soon-to-open dispensaries in four cities from Miami to Daytona Beach and across to Spring Hill
• Florida is on the verge of a “massive medical marijuana boom” as the pain-conscious retirement community grows and residents’ attitudes overwhelmingly favor openness toward legal medical marijuana
• Red White & Bloom is also putting together a strong retail cannabis position in Michigan and Florida

Multistate cannabis sector operator Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) is off to a quick start in building its high-quality flower resource for product inventory at dispensaries throughout Florida. Red White & Bloom expects to launch growing operations in 30 modular pods at its Apopka, Florida cultivation location by Dec. 1, adding 19,200 square feet of production expected to deliver $30 million in annual revenues to the company. The pods were approved by the state health department’s Office of Medical Marijuana Use (“OMMU”) with licensing granted just before Halloween and five are already in use for plant growth while the remainder are being fast-tracked for output, according to a Nov. 4 news release (https://ibn.fm/13yLA). Red White & Bloom is a retail cannabis brand builder focused on Florida ahead of a “massive medical marijuana boom” expected to sweep the state as prohibitionist policies recede (https://ibn.fm/nEZQV). “We have nurtured our strains to produce high quality flower in the Florida climate while producing high yields, industry-leading THC percentages and superior terpene content,” Jim Frazier, the general manager of Red White & Bloom’s Florida cultivation subsidiary, stated in the news release. “The grow pods provide us with speed to market capabilities which are needed for RWBFL to meet and exceed expectations for generating profitable revenue early in 2022.” The company’s two cultivation centers in Florida are working aggressively to supply existing and soon-to-open dispensaries with needed product. The final phase of Red White & Bloom’s strategic rollout in the state involves bringing its 113,000-square-foot indoor growing facility in Sanderson online, about 120 miles northwest of the Apopka location. The OMMU released a survey of the market this year that states 89 percent of Floridians who responded to its questions think adults should be allowed to legally use medical marijuana, and as more pain-weary senior citizens seek the Florida sunshine the number is likely to increase (https://ibn.fm/K6Tug). As a company aiming to become one of the top three multi-state operators active in the United States’ legal cannabis and hemp sectors, Red White & Bloom is also seeking toe-hold in the recreational adult use market in Michigan, Illinois, Florida, Arizona and California, and across of international opportunity fields for hemp. The company received adult recreational use prequalification status from Michigan in September and authorization to market itself to a population of about 10 million people through 18 dispensaries (eight of which are already operating), four cultivation facilities indoors and outdoors, and “significant company-owned real estate holdings,” according to the company’s Sept. 7 statement (https://ibn.fm/VbA0Q). “In only its second full year of adult-use sales, Michigan’s legal cannabis market is emerging from the pandemic ripe with opportunity. With a run-rate behind only California and Colorado, Michigan’s early 2021 sales have put the state on pace to not only break the $2 billion sales threshold but, also blow right past it,” CEO and Chairman Brad Rogers stated. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• StraightUp marked 2021 with strategic opportunities in the United States and Peru
• These projects were selected by management based on past exploration and proven reserves in these regions
• 2021 also marked the year StraightUp up-listed to the OTCQB Venture Market in the United States
• StraightUp is optimistic about 2022

For the 2021 fiscal and calendar year, StraightUp Resources (CSE: ST) (OTCQB: STUPF) set out on an aggressive asset acquisition plan, coupled with an exploration program that would be the highlight of the year. Thus far, it has acquired the West Cat Mine in Nevada, along with the Ferdinand Gold Project and Bear Head Gold Project, both located in western Ontario (https://ibn.fm/kPFqY). However, these acquisitions do not aptly represent its commitment to maximizing shareholder wealth as its aggressive exploration program. StraightUp, at the beginning of the year, broke down its 2021 exploration program into four elements:

1. Historical data review, compilation, and interpretation
2. Examining historical drill core (ENDM core library, Red Lake)
3. Geological mapping and sampling
4. Geophysical surveys

The objective was to add new 2021 data to enhance interpretations, locate prime locations for drilling holes and conduct soil sampling to inform the company’s investment decisions and guarantee a return on its investment. This exploration program was firmly founded on science, mainly SGH soil sampling, primitive-mantle normalized trace element geochemistry, and geophysical surveys, among others (https://ibn.fm/90yBO). So far, these efforts have allowed StraightUp to acquire prime properties with tremendous potential to maximize shareholder wealth. It has also allowed the company to expand its market reach, with its entry into the American market with the West Cat Mine acquisition in Nevada and the Peruvian market with the exclusive rights to purchase of the Mallay silver mine. StraightUp also made a significant move to expand its access to investors by up-listing to the OTCQB Venture Market in the United States (https://ibn.fm/urNtt). It comes just in time as the company grows its asset portfolio, opening its doors to millions of investors within the United States, particularly as it plans to execute on its next phase of growth. In addition, the company hopes to benefit shareholders through increased trading liquidity through this move, ultimately adding more value for them and their investment. Over the past year, the company has made some important gains and its management has expressed optimism for the 2022 financial year in growing shareholder value. For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://ibn.fm/STUPF

• Rositano Jr. is looking for the Fan Pass Live artist platform to expand its global reach and become a household name in the near future
• The live interview put Fan Pass into the spotlight and introduced the platform to Hype’s estimated audience of 300,000 readers and its social media following of over 484k on Instagram and over 189k on Twitter
• Rositano Jr. made it clear during the interview that great things are planned from Friendable for the Fan Pass platform in the new year

Music has always found a place in the lives of Robert A. Rositano Jr. and his brother (and business partner) Dean. Growing up, Dean was a touring musician, and as a family, the Rositanos have always been enchanted by artists and the music industry. In a recent interview with The Hype Magazine, Rositano Jr., the CEO of Friendable (OTC: FDBL), sat down for a live discussion with the magazine’s Editor-in-Chief, Jerry Doby, to discuss his company’s innovative artist streaming platform, from inception to plans for the future (https://ibn.fm/Vu4bs). The Hype Magazine has an audience reach of over 300,000, with 484k followers on Instagram and over 189k Twitter followers. The company is hoping to use this interview and the fan base of The Hype Magazine to extend the exposure of the Fan Pass platform and its offering to both fans and artists. “First, I’d like to thank our team at Lobeline Communications for seeking out this industry-specific opportunity to share the Fan Pass story, platform, and opportunity with the music artist community. The traction and attention received by the company since onboarding the Lobeline team have been very apparent as we collectively continue elevating our brand and making strides on many levels,” explained Rositano Jr. The interview presented informative talking points, spanning the history of past applications and the birth of the Fan Pass platform to what the company’s vision for five years in the future might look like. The Rositano brothers began working with artists before the concept of live streaming even existed. The vision eventually turned into “America’s Biggest” in 2005. Artists would record music in a San Francisco studio, where it would be archived onto a website. A $5k pool would be offered each month and given to the winner of what Rositano Jr. referred to as “an offline battle of the bands.” The platform only lasted 90 days before another company acquired it but never fulfilled its full potential after being sold. Fan Pass was already in the works long before the pandemic reared its ugly head. In fact, the pandemic forced the company to regroup and figure out how they could retarget the entire platform to better serve the artists and fans who were suffering because of it. Even with all of the new features that have been released this year, Rositano Jr. hinted about several opportunities coming with 2022. One of these opportunities involves artists being included on playlists through partnerships with celebrities – but Rositano Jr. remained tight-lipped on the matter, saying that he was not ready to disclose any more details about it at this point. Doby also asked about Fan Pass going global, to which Rositano Jr. responded that the platform is currently #70 in Vietnam, so going international is certainly an opportunity they plan to explore in the coming months. As for the future, Rositano Jr. has high hopes for the Fan Pass Live artist platform. Five years from now, he wants to see Fan Pass become a household name with hundreds of thousands of artists launching their careers and earning revenue through the platform. The Friendable CEO hopes that even though venues are beginning to reopen, artists will be willing to augment their tours to include virtual performances, if for no other reason than to accommodate those who are hesitant to go to a live performance or those who can’t afford the traditional VIP experience. He concluded by saying it was very exciting to be interviewed by a publication that truly understands the music industry, musicians, and more specifically, indie artists, like The Hype Magazine does. “We intend to continue nurturing a relationship that expands beyond this initial interview, as indie artists are seeking a solution that brings recognition, builds fan bases, drives revenue, and, ultimately, launches careers,” Rositano Jr. underlined. “We believe Fan Pass is the solution. A new year is upon us shortly, and we have lots in store as we continue to build on our success.” For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• LQwD’s proprietary, multi-pronged Lightning Network platform provides easier access to a decentralized network and payment solution
• The platform makes it possible for users to create and manage Lightning Network nodes easily; make transactions securely, privately, and almost instantaneous; create channels on the Network with effective routing; request and manage liquidity more efficiently
• Bitcoin experts have predicted that the price of the cryptocurrency will continue to climb through 2021, potentially hitting highs around USD$80,000 before surging to USD$250,000 by 2025 and a goal of USD$5 million per Bitcoin by 2030
• The Lightning Network is a second-layer protocol sitting above the Bitcoin blockchain and will advance Bitcoin from a store-of-value to a global monetary network through payment utility. LQwD expects the Network to increase the growing number of active blockchain wallets by increasing Bitcoin scalability, transaction speeds and lowering fees

LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a financial technology company with a mission of developing institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption, and the utility and scalability of Bitcoin, has announced the launch of its proprietary multi-pronged, Lightning Network Software as a Service (SaaS) – LQwD.tech. The platform provides easier access to a decentralized network and payment solution. This SaaS will allow B2B markets, investors, and others to gain broader access, more efficient liquidity, and seamless usage of the global payments infrastructure. The platform creates the potential for multiple nodes across channels, with the potential to lower transaction fees and a more user-friendly option (https://ibn.fm/HXWz6). Tune into LQwD CEO, Shone Anstey discusses the recently launched platform here. “The Lightning Network is an extremely dynamic new global monetary network that’s growing exponentially, and we’re excited and fortunate to be a solutions provider in the space,” Albert Szmigielski, LQwD’s Chief Technology Officer, said. Szmigielski explained that developing countries such as El Salvador are using and seeing significant adoption of cryptocurrencies, while one of the world’s largest social media platforms – Twitter – is making global tipping on the Lightning Network mainstream with its tipping feature called Tips. “Needless to say, we’re looking forward to becoming a major contributor to (and supporter of) Bitcoin’s scaling layer – the Lightning Network.” With the launch of LQwD.tech, the company will deploy a portion of its Bitcoin holdings to secure additional nodes and provide liquidity to the platform, enabling LQwD to earn transaction fees on the rapidly growing payment network. This platform empowers institutions, businesses, and investors, making integration with the Lightning Network easy. The design was created to be scalable and adaptive to the incredible growth of the Lightning Network, which allows for millions of Bitcoin transactions in seconds. LQwD’s platform makes it possible for users to:

• Easily create and manage Lightning Network nodes
• Make transactions securely, privately, and almost instantly using the Network
• Create channels on the Network with effective routing
• Request and manage liquidity more efficiently

Cryptocurrency experts have predicted that the price of Bitcoin will continue to climb through 2021, potentially hitting highs around $80,000 before surging to $250,000 by 2025 and a goal of $5 million per Bitcoin by 2030 (https://ibn.fm/m9TZr). The Lightning Network is a second-layer protocol sitting above the Bitcoin blockchain and will advance Bitcoin from a store-of-value to a global monetary network through payment utility. LQwD expects the Network to increase the growing number of active blockchain wallets by increasing Bitcoin scalability and lowering fees. The Network is intended to facilitate faster micro-transactions, thus allowing for the mass adoption of Bitcoin. For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• Pharmaceutical company Tryp Therapeutics is investigating the potential of synthetic psychedelic drug candidates to treat unmet medical needs
• The company is evaluating two drug products labeled TRP-8802 and TRP-8803 for treating fibromyalgia, phantom limb pain, complex regional pain syndrome and select eating disorders
• The company has filed its first two INDs with the FDA for planned Ph 2a clinical trials relating to fibromyalgia and eating disorder treatments
• In the wake of changes recommended by the FDA to the eating disorders trial, Tryp is in the process of updating its protocols and patient consent form to meet the FDA’s expectations
• Tryp anticipates completing preparations for the phantom limb pain and complex regional pain syndrome studies in partnership with investigators in the University of California system

Pioneering psychedelic medicine pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is advancing toward the launch of four Phase 2a studies of its two novel drug candidates, laying the groundwork for clinical trials at the University of Michigan and the University of Florida for treating pain and eating disorders, which includes making some adjustments to one of the trials recently requested by the FDA. Tryp’s synthetic psilocybin program includes the development of drug candidates TRP-8802 and TRP-8803 for treating fibromyalgia, phantom limb pain, complex regional pain syndrome (“CRPS”) and select eating disorders. Tryp filed an IND with the U.S. Food and Drug Administration in September for treating overeating disorders in Florida, and filed its second IND application earlier this month for fibromyalgia testing in Michigan (https://ibn.fm/fzSc4). The FDA asked Tryp to change the scope of its eating disorders trial so that the initial Florida investigation can focus on patients with binge eating disorder. Because the company was also planning to recruit patients with a range of overeating disorders including Prader-Willi Syndrome (“PWS”) and hypothalamic obesity disorder resulting from the removal of a brain tumor, the FDA asked the company to break off the hypothalamic obesity disorder testing and file a separate IND for a potential fifth clinical study regarding those patients. “We appreciate the feedback from the FDA on our clinical activities for binge eating disorder and hypothalamic obesity patients,” Tryp Chairman and CEO Greg McKee stated in a Nov. 18 news release (https://ibn.fm/JzrbX). “We look forward to advancing our synthetic psilocybin programs for the benefit of patients and clinicians alike.” McKee stated the company would submit a formal response to the FDA within 10 days of the news release outlining changes to the eating disorders clinical trial and its informed consent form, and added that the FDA indicated it would respond to those modifications within 30 days. McKee told Trader TV that the company is excited to begin dosing patients in the Florida eating disorder study and the Michigan fibromyalgia study as soon as the final steps are taken care of, and that the company is working with educational partners in the University of California system to prepare for the anticipated phantom limb pain and CRPS trial filings (https://ibn.fm/qN79d). “Compared to other companies in the psychedelic drug development space, we’re going to have these four phase 2a clinical trials, which puts us in pretty rarefied air on top of the fact that we’re working in some therapeutic areas with patients that that really not a lot of other companies are looking at this time,” McKee said. The clinical trials will use TRP-8802. TRP-8803 will be developed as a proprietary, synthetic psilocybin drug candidate designed to advance the company through Phase 2b clinical trials that evaluate the drug candidate’s ability to penetrate the natural blood-brain barrier to more effectively alleviate pain and addiction, using a novel route of administration that will lead to more precise control over the patient’s psychedelic experience during the treatment. Tryp plans to administer TRP-8802 in 25 mg oral dosing, and was enthused by the report of Compass Pathways at the recent Wonderland: Miami conference where Compass reported its own success using 25 mg oral dosing of psilocybin in combination with psychotherapy to treat resistant depression, which Tryp regards as validation of its hypothesis (https://ibn.fm/tdtpR). For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Dr. Matthew Johnson discussed psilocybin for tobacco smoking cessation at this year’s Psychedelic Medicine Business Event: Wonderland, in Miami
• He shared preliminary findings from his recent study on substance use disorder, along with the participants’ feedback on their experience
• Dr. Johnson, along with Mydecine, are set to embark on their clinical study utilizing MYCO-001 for smoking cessation, set to commence in early 2022, building on the success of this recent study
• Mydecine is also set to support Dr. Johnson’s concurrent NIDA grant-funded study through the provision of MYCO-001 for research

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), back in September 2021, announced its seamless phase 2/3 smoking cessation clinical trial that will launch in early 2022. The study, which will be led by Johns Hopkins University’s (“JHU”) Dr. Matthew Johnson, will evaluate the administration of MYCO-001, a 99% pure version of psilocybin, with a structured smoking cessation treatment program in nicotine-dependent individuals (https://ibn.fm/cKxuV). This study builds on similar research initiated by JKU back in 2014, under the leadership of Dr. Johnson, a world-renowned psychedelic drug researcher. This preliminary study showed that 80% of the subjects achieved abstinence at six months following 2-4 oral doses of psilocybin, coupled with extensive cognitive behavioral therapy (“CBT”). It also builds on an ongoing 100-subject randomized trial for which Dr. Johnson presented the interim results at this year’s Psychedelic Medicine Business Event: Wonderland in Miami. Scheduled for November 8-9, 2021, this event was deemed the largest psychedelic medicine business event ever. It covered various topics surrounding the psychedelics industry, including the path to federal acceptance, AI-driven psychedelic drug discovery, precision medicine and psychedelics, and the future of psychedelics. In addition, Dr. Johnson covered psilocybin for tobacco smoking cessation, mainly covering the findings from his research thus far (https://ibn.fm/R950g). Dr. Johnson’s study involved 100 patients considered treatment-resistant smokers and span across 12 months. These participants were randomized to psilocybin or the nicotine patch, each receiving the same cognitive-behavioral therapy. However, the study involved only one psilocybin session. Dr. Johnson noted that after 12 months, 59% of the patients who received the psilocybin treatment remained abstinent, while only 28% of those who received the nicotine patch remained abstinent. This positive data played an integral role in ROTH Capital’s report published on November 16th reiterating Mydecine’s Buy rating and C$3/share 12-month price target following the release of their 3Q21 results. The participants in the study appreciated Dr. Johnson’s work, citing psilocybin’s benefits and how life-changing the entire experience was. “Primarily, I would say it made me understand that my identity is this construct,” one noted. “Seeing that which happened during the psilocybin experiences and being reminded of, and understanding, life as an unspeakably marvelous adventure of existence,” reckoned another. Dr. Johnson is currently leading another separate study, funded by the National Institute on Drug Abuse (“NIDA”). This marks the first time in over 50 years that the United States government has funded a study of a psychedelic compound for therapeutics. Mydecine will supply MYCO-001 for this study and is excited to be part of Dr. Johnson’s research. “We are excited to support Dr. Johnson and his team in this concurrently running study, which we believe will add a significant benefit to support our 2/3 seamless design. We have made significant progress advancing our MYCO-001 clinical trials for smoking cessation to date with JHU,” noted Josh Bartch, the Chief executive Officer (“CEO”) of Mydecine. “The opportunity to play an integral role in this landmark study by supplying our lead drug candidate, not only offers a significant opportunity to further advance our drug development through safer and more viable results, but demonstrates Mydecine’s leadership position in the emerging psychedelic-assisted psychotherapy industry,” he added (https://ibn.fm/GKO9v). Mydecine has expressed its optimism for the phase 2/3 trial, along with future studies on psilocybin to treat other indications in mental health and addiction, focusing on two main indications- smoking cessation and post-traumatic stress disorder (“PTSD”). The company is confident that the results from these studies will help patients dealing with such conditions and support its overall mission going forward, ultimately making MYCO-001 possibly the first psilocybin therapy to be approved for any indication. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Research and Markets released new online gaming industry report, expecting significant growth with CAGR of 11.94% between 2021-2026
• Swedish University study suggests rapid growth in online gaming resulted from COVID-19 lockdowns
• Grand View Research report predicts online gambling market will reach $127.3 billion by 2027
• PLGNF provides multi-tenant gateway that enables online operators to offer popular games that include Live Dealer Casino, E-Table Games, and Daily Fantasy Sports
• PLGNF’s privacy-focused software enables seamless integration at operator level, allows users to access the platform without sharing sensitive data or requiring app store download

Research and Markets recently released a report titled “Online Gambling Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021-2026)” that highlights future growth prospects for the online gaming industry (https://ibn.fm/dmk2N). Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF), a SaaS technology company focused on developing and licensing digital content for the growing global iGaming industry, is positioned to take a significant share of the increasing market by offering a first-rate gaming experience while ensuring total user privacy. According to the report, long-term interest in online gaming emerged due to COVID-19 lockdowns that drove consumers online to mediate the economic, social, and psychological effects of government restrictions. Specifically, research conducted by the Lund University in Sweden suggests that the forced closure of sporting events resulted in a surge of interest in online gambling platforms. “In response to the closure of many gambling establishments, several operators went digital,” reads the summary of the report (https://ibn.fm/hqErc). “Many players expanded their online gambling offerings, and bingo operators moved their offerings online, which positively impacted the market.” Analysts at Research and Markets expect a CAGR of 11.94% between 2021-2026, with online betting leading the sector as the fastest-growing segment during the forecast period. Innovations in technology such as artificial intelligence, machine learning, and cashless payments are expected to spur industry growth, along with a growing female segment contributing substantially to the increasing user base. According to Grand View Research, the online gambling market is expected to reach $127.3 billion by 2027 (https://ibn.fm/bKb1A), with much of that growth coming from the United States and Asia. PLGNF provides an innovative multi-tenant gateway that enables online operators to offer users popular games such as Live Dealer Casino, E-Table Games, and Daily Fantasy Sports. The company’s proprietary software combines high-definition live streaming dealers with state-of-the-art augmented reality betting to provide an authentic casino experience based in Las Vegas. In addition, the company’s privacy-enhanced software enables seamless integration at the operator level while allowing users to access the platform without sharing sensitive data or requiring an app store download. PLGNF’s products are ideal turn-key solutions for online casinos, land-based operators, sportsbook operators, media groups, and big database companies. With a portfolio of IP-protected assets and high barriers to entry, the company is positioned favorably within the rapidly growing iGaming industry. For more information, visit the company’s website at www.Playgon.com. NOTE TO INVESTORS: The latest news and updates relating to PLGNF are available in the company’s newsroom at https://ibn.fm/PLGNF

• U.S.-based mobile tech services provider FingerMotion is laser-focused on the Chinese phone consumer market, building revenues primarily from SMS and MMS services there but expanding into insurance data services with other corporate partners
• The company’s trademarked big data platform Sapientus handles over half a million transactions daily for its mobile payment and recharge services
• Analysts have noted the huge potential for upgrade services in China given consumer interest in replacing their high-end smartphones and acquiring 5G network capability
• Although there were 180 million 5G users at the end of last year, the government has promoted the fast-speed network and among 1.62 mobile phone subscriptions, 90 percent of those who replied to a Strategy Analytics survey stated they want to upgrade to a 5G phone

China’s hungry smartphone market appears poised for a very strong upgrade cycle if analysis by Strategy Analytics holds true in regard to the country’s technology buying trends. The market watch company reported on a recent survey that found 35 percent of high-end smartphone users in the Asian nation will change their phones in the next six months and that 90 percent of users want their next smartphone to be 5G-enabled, according to a subsequent review by China Internet Watch (https://ibn.fm/OcjbY). The appetite for mobile products and services among China’s 1.4 billion-person user base underscores the strength of communications technology solutions provider FingerMotion (OTCQX: FNGR) in positioning itself to deliver new value-added phone products to China’s consumers. Seeking Alpha recently noted that there were 180 million 5G subscribers as of the end of last year but 1.62 billion mobile phone subscriptions within China (thanks largely to the fact that many Chinese consumers prefer to have multiple phones), showing the potential for phone upgrades (https://ibn.fm/WeGD8). FingerMotion’s primary revenue stream has been from short and multimedia messaging (SMS and MMS) services but the company recently announced the addition of two brands partnered with a large American insurance company to provide mobile device protection program services such as coverage of broken phone screens, accidental damage repairs and compensation, and older device trade-ins (https://ibn.fm/W4lwF). The partnership is emblematic of FingerMotion’s new forays into the insurtech market by drawing on the big data capabilities of its Sapientus platform, which handles over half a million transactions daily for its mobile payment and recharge services, and using those big data resources to help insurers efficiently process claims while screening for fraud and abuse, thereby providing FingerMotion a new revenue stream in the process. FingerMotion gained the attention of global insurer Pacific Life earlier this year, inking an agreement to provide consumer risk data for Pacific Life’s Re-insurance division in China (https://ibn.fm/gLQiB). FingerMotion’s mobile device protection services are expected to launch early next year, although beta testing is already taking place this month in Shanghai, Guangdong, Anjui, Zhejiang, and Henan provinces. “This latest development demonstrates the flexibility of our business model to explore ways to monetize our vast active user base,” CEO Martin Shen stated in regard to the protection program services. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Company releases positive results from preclinical study focusing on psilocybin program CYB003
• Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare
• Results indicate less patient variability, faster onset of action, shorter duration of effect and improved brain penetration

According to the National Institute of Mental Health, some 17.3 million Americans, or more than 7% of the country’s entire population, suffer from major depressive disorder (“MDD”) (https://ibn.fm/0GSuV). This demographic can look to Cybin (NEO: CYBN) (NYSE American: CYBN) for help; the pharmaceutical company has announced positive results from a preclinical study focusing on CYB003, one of its psilocybin programs (https://ibn.fm/mu4aT). “Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare, but few companies have addressed the well-known limitations and side effects of oral psilocybin,” said Cybin CEO Doug Drysdale. “Cybin has always strived to develop safer and more effective therapies for patients, which has guided our multiple psilocybin programs: CYB001, CYB002, and CYB003.” According to the company, positive CYB003 preclinical findings demonstrate distinctive advantages for its newly developed novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health. Those results “may have wide-reaching implications for the treatment of MDD, as well as alcohol use disorder (‘AUD’), with less patient variability, faster onset of action, shorter duration of effect and improved brain penetration,” the company reported. According to previous research, oral psilocybin appears to be efficacious in treating mental health disorders, especially MDD, but the treatment does have significant limitations, including slow onset of action, extended duration of effect and a variability in response among patients. Cybin’s CYB003 program is designed to maintain the benefits of oral psilocybin while addressing the challenges. Based on its multispecies, preclinical studies, Cybin has been able to do just that. The company’s CYB003 program showed faster onset of action equates to less down time in the clinic before effects begin; half the duration of effect translates to shorter clinic days or more patients per day; more predictable dose effects create a safer and more effective patient response; lowered peripheral exposure diminishes the risk of nausea; and better brain penetration suggests lower overall dose needed to achieve clinical efficacy. “While we are all encouraged by the benefits of psilocybin, we need to transparently and openly discuss its limitations if we are to translate psychedelics to therapeutics for patients in need,” said Drysdale. “The majority of current clinical studies are based on psilocybin. We have taken the necessary steps to potentially unlock the powerful benefits of psychedelics and engineer a superior molecule as demonstrated by the data. We are on a mission to make ethical, safe scientific progress to advance the care and treatment of mental health patients. Our goal has always been to be a leader in creating the best therapy for patients; today, we move one step closer.” For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN